Accurate Detection of α‐Synuclein Seeds in Cerebrospinal Fluid from Isolated Rapid Eye Movement Sleep Behavior Disorder and Patients with Parkinson's Disease in the DeNovo Parkinson (DeNoPa) Cohort
Open Access
- 13 February 2023
- journal article
- research article
- Published by Wiley in Movement Disorders
- Vol. 38 (4) , 567-578
Abstract
Background: Misfolded α‐synuclein (αSyn) aggregates (αSyn‐seeds) in cerebrospinal fluid (CSF) are biomarkers for synucleinopathies such as Parkinson's disease (PD). αSyn‐seeds have been detected in prodromal cases with isolated rapid eye movement sleep behavior disorder (iRBD).Objectives: The objective of this study was to determine the accuracy of the αSyn–seed amplification assay (αS‐SAA) in a comprehensively characterized cohort with a high proportion of PD and iRBD CSF samples collected at baseline.Methods: We used a high‐throughput αS‐SAA to analyze 233 blinded CSF samples from 206 participants of the DeNovo Parkinson Cohort (DeNoPa) (113 de novo PD, 64 healthy controls, 29 iRBD confirmed by video polysomnography). Results were compared with the final diagnosis, which was determined after up to 10 years of longitudinal clinical evaluations, including dopamine‐transporter–single‐photon emission computed tomography (DAT‐SPECT) at baseline, CSF proteins, Movement Disorder Society–Unified Parkinson's Disease Rating Scale, and various cognitive and nonmotor scales.Results: αS‐SAA detected αSyn‐seeds in baseline PD‐CSF with 98% accuracy. αSyn‐seeds were detected in 93% of the iRBD cases. αS‐SAA results showed higher agreement with the final than the initial diagnosis, as 14 patients were rediagnosed as non‐αSyn aggregation disorder. For synucleinopathies, αS‐SAA showed higher concordance with the final diagnosis than DAT‐SPECT. Statistically significant correlations were found between assay parameters and disease progression.Conclusions: Our results confirm αS‐SAA accuracy at the first clinical evaluation when a definite diagnosis is most consequential. αS‐SAA conditions reported here are highly sensitive, enabling the detection of αSyn‐seeds in CSF from iRBD just months after the first symptoms, suggesting that αSyn‐seeds are present in the very early prodromal phase of synucleinopathies. Therefore, αSyn‐seeds are clear risk markers for synuclein‐related disorders, but not for time of phenoconversion. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.Keywords
Funding Information
- Foundation for the National Institutes of Health (RF1AG055053, RF1AG059321)
- Michael J. Fox Foundation (MJFF‐21233)
This publication has 47 references indexed in Scilit:
- Delayed emergence of a parkinsonian disorder or dementia in 81% of older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder: a 16-year update on a previously reported seriesSleep Medicine, 2013
- Disease duration and the integrity of the nigrostriatal system in Parkinson’s diseaseBrain, 2013
- Incidence and Pathology of Synucleinopathies and Tauopathies Related to ParkinsonismJAMA Neurology, 2013
- α-Synuclein Aggregation and Modulating Factors2012
- Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Scale presentation and clinimetric testing resultsMovement Disorders, 2008
- International multicenter pilot study of the first comprehensive self‐completed nonmotor symptoms questionnaire for Parkinson's disease: The NMSQuest studyMovement Disorders, 2006
- The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive ImpairmentJournal of the American Geriatrics Society, 2005
- AGEING AND PARKINSON'S DISEASE: SUBSTANTIA NIGRA REGIONAL SELECTIVITYBrain, 1991
- Development and validation of a geriatric depression screening scale: A preliminary reportJournal of Psychiatric Research, 1982
- “Mini-mental state”Journal of Psychiatric Research, 1975